AVTE Logo

Aerovate Therapeutics, Inc. (AVTE) 

NASDAQ$2.47
Market Cap
$71.32M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
120 of 924
Rank in Industry
82 of 527

AVTE Insider Trading Activity

AVTE Median Price and Trade Amounts History Chart

Statistics of Insider Transactions

Amount of Insider Buys and Sells

Buys
$1,549,94414
Sells
$5,235,5402296

Related Transactions

RA CAPITAL MANAGEMENT, L.P.1$1.55M0$0$1.55M
GRAYZEL DAVID S.director0$01$334,478$-334,478
Verwijs MarinusCHIEF TECHNICAL OFFICER0$04$599,571$-599,571
Gillies HunterCHIEF MEDICAL OFFICER0$05$767,410$-767,410
Eldridge George ASEE REMARKS0$03$967,049$-967,049
NOYES TIMOTHY PCHIEF EXECUTIVE OFFICER0$04$993,705$-993,705
Dake Benjamin TSEE REMARKS0$05$1.57M$-1.57M

About Aerovate Therapeutics, Inc.

Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. The company focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. Aerovate Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

Insider Activity of Aerovate Therapeutics, Inc.

Over the last 12 months, insiders at Aerovate Therapeutics, Inc. have bought $1.55M and sold $5.24M worth of Aerovate Therapeutics, Inc. stock.

On average, over the past 5 years, insiders at Aerovate Therapeutics, Inc. have bought $71.77M and sold $8.79M worth of stock each year.

Highest buying activity among insiders over the last 12 months: RA CAPITAL MANAGEMENT, L.P. () — $1.55M.

The last purchase of 928,110 shares for transaction amount of $1.55M was made by RA CAPITAL MANAGEMENT, L.P. () on 2024‑06‑17.

List of Insider Buy and Sell Transactions, Aerovate Therapeutics, Inc.

2024-06-17PurchaseRA CAPITAL MANAGEMENT, L.P.
928,110
0.2418%
$1.67$1.55M+43.03%
2024-06-14SaleEldridge George ASEE REMARKS
15,000
0.0586%
$25.03$375,450-90.45%
2024-06-14SaleVerwijs MarinusCHIEF TECHNICAL OFFICER
10,600
0.0413%
$25.00$265,000-90.45%
2024-06-13SaleGillies HunterCHIEF MEDICAL OFFICER
6,000
0.0229%
$24.50$147,000-90.40%
2024-05-17SaleGillies HunterCHIEF MEDICAL OFFICER
4,000
0.0136%
$21.08$84,332-88.19%
2024-05-16SaleNOYES TIMOTHY PCHIEF EXECUTIVE OFFICER
10,000
0.0347%
$21.58$215,755-88.91%
2024-05-02SaleVerwijs MarinusCHIEF TECHNICAL OFFICER
1,981
0.007%
$21.02$41,631-88.19%
2024-05-01SaleNOYES TIMOTHY PCHIEF EXECUTIVE OFFICER
11,357
0.0386%
$20.34$230,946-88.24%
2024-04-17SaleGillies HunterCHIEF MEDICAL OFFICER
4,000
0.0143%
$22.38$89,522-89.02%
2024-04-17SaleDake Benjamin TSEE REMARKS
6,853
0.0245%
$22.37$153,327-89.02%
2024-04-16SaleNOYES TIMOTHY PCHIEF EXECUTIVE OFFICER
10,000
0.0375%
$24.70$246,971-89.54%
2024-04-10SaleEldridge George ASEE REMARKS
7,500
0.0268%
$26.85$201,392-90.86%
2024-04-09SaleGRAYZEL DAVID S.director
11,882
0.0428%
$28.15$334,478-91.19%
2024-04-01SaleEldridge George ASEE REMARKS
12,495
0.0455%
$31.23$390,208-91.95%
2024-04-01SaleDake Benjamin TSEE REMARKS
3,325
0.0124%
$31.97$106,317-91.95%
2024-04-01SaleVerwijs MarinusCHIEF TECHNICAL OFFICER
5,300
0.0181%
$29.19$154,697-91.95%
2024-04-01SaleNOYES TIMOTHY PCHIEF EXECUTIVE OFFICER
10,000
0.035%
$30.00$300,033-91.95%
2024-03-28SaleGillies HunterCHIEF MEDICAL OFFICER
9,000
0.0322%
$29.50$265,500-91.62%
2024-03-27SaleDake Benjamin TSEE REMARKS
11,068
0.0393%
$27.97$309,519-91.30%
2024-03-25SaleDake Benjamin TSEE REMARKS
3,432
0.0129%
$28.01$96,119-90.72%
Total: 143
*Gray background shows transactions not older than one year

Insider Historical Profitability

<0.0001%
RA CAPITAL MANAGEMENT, L.P.
7893678
27.3379%
$19.5M20<0.0001%
GRAYZEL DAVID S.director
14502
0.0502%
$35,819.9411<0.0001%
Sofinnova Venture Partners X, L.P.10 percent owner
3758686
13.0173%
$9.28M10<0.0001%
Katabi Maha
3758686
13.0173%
$9.28M10<0.0001%
Atlas Venture Fund XII, L.P.10 percent owner
3103879
10.7496%
$7.67M10<0.0001%
*Gray background shows insiders who have made transactions during last year

Historical Insider Profitability vs. Competitors

$2,600,095
110
13.50%
$70.91M
$4,898,715
46
40.74%
$73.28M
$329,102,560
42
30.96%
$73.82M
$542,300
40
-14.44%
$67.8M
$22,110,933
34
30.18%
$67.48M

AVTE Institutional Investors: Active Positions

Increased Positions50+60.24%8M+29.15%
Decreased Positions33-39.76%6M-20.04%
New Positions25New6MNew
Sold Out Positions21Sold Out5MSold Out
Total Postitions100+20.48%30M+9.11%

AVTE Ownership Change vs Market

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
Ra Capital Management, L.P.$22,337.0031.7%9.19M00%2024-12-31
Sofinnova Investments, Inc.$9,134.0012.96%3.76M00%2024-12-31
Tcg Crossover Management, Llc$5,445.007.73%2.24M00%2024-12-31
Atlas Venture Life Science Advisors, Llc$4,372.006.2%1.8M00%2024-12-31
Braidwell Lp$3,500.004.97%1.44M+1MNew2024-12-31
Logos Global Management Lp$3,402.004.83%1.4M+1MNew2024-12-31
Vanguard Group Inc$2,435.003.46%1M-149,974-13.02%2024-12-31
Blackrock, Inc.$2,370.003.36%975,423+21,747+2.28%2024-12-31
Adar1 Capital Management, Llc$2,255.003.2%928,016+814,941+720.71%2024-12-31
Allostery Investments Lp$2,067.002.93%850,684+850,684New2024-12-31

Financial Ratios

Summary
Comparison with Competitors

Analyst Recommendations

Analyst Price Targets

Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.